ADARx Pharmaceuticals, Inc. (ADRX)
Data as of , from SEC Form 4 filings.
See up to 3 months of ADRX. The 7-day demo opens the 1M and 3M ranges and puts ADRX on your watchlist.
Start 7-day demoLatest ADRX insider trades
About ADARx Pharmaceuticals, Inc. (ADRX)
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
- 2026
- XNAS
ADRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 13 | 5,161,516 | $87.75M |
| Grant or award | 5 | 1,962,958 | |
| Other acquisition / disposition | 76 | 173,447,078 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ADRX insider transactions (Form 4)
9411 Form 4 filings on record, the earliest from Sep 28, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Erez Chimovits - Director | Other | Common Stock | 7,127,019 | - footnote F1 | - | |
| Erez Chimovits - Director | Other | Common Stock | 1,333,975 | - footnote F1 | - | |
| Erez Chimovits - Director | Other | Common Stock | 513,067 | - footnote F1 | - | |
| Erez Chimovits - Director | Other | Common Stock | 256,448 | - footnote F1 | - | |
| Erez Chimovits - Director | Open-market purchase | Common Stock | 61,516 footnote F2 | $17.00 | $1.05M | |
| Erez Chimovits - Director | Other | Series A Preferred Stock | 7,127,019 | $0.00 | - | |
| Erez Chimovits - Director | Other | Series B Preferred Stock | 1,333,975 | $0.00 | - | |
| Erez Chimovits - Director | Other | Series B-1 Preferred Stock | 513,067 | $0.00 | - | |
| Erez Chimovits - Director | Other | Series C Preferred Stock | 256,448 | $0.00 | - | |
| ||||||
| Carl L. Gordon - Director | Other | Common Stock | 10,690,530 | - footnote F1 | - | |
| Carl L. Gordon - Director | Other | Common Stock | 2,000,962 | - footnote F1 | - | |
| Carl L. Gordon - Director | Other | Common Stock | 769,601 | - footnote F1 | - | |
| Carl L. Gordon - Director | Other | Common Stock | 564,187 | - footnote F1 | - | |
| Carl L. Gordon - Director | Open-market purchase | Common Stock | 300,249 footnote F2 | $17.00 | $5.10M | |
| Carl L. Gordon - Director | Other | Common Stock | 7,127,019 | - footnote F1 | - | |
| Carl L. Gordon - Director | Other | Common Stock | 1,333,975 | - footnote F1 | - | |
| Carl L. Gordon - Director | Other | Common Stock | 513,067 | - footnote F1 | - | |
| Carl L. Gordon - Director | Other | Common Stock | 256,448 | - footnote F1 | - | |
| Carl L. Gordon - Director | Open-market purchase | Common Stock | 61,516 footnote F2 | $17.00 | $1.05M | |
| Carl L. Gordon - Director | Open-market purchase | Common Stock | 588,235 footnote F2 | $17.00 | $10.00M | |
| Carl L. Gordon - Director | Other | Series A Preferred Stock | 10,690,530 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series B Preferred Stock | 2,000,962 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series B-1 Preferred Stock | 769,601 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series C Preferred Stock | 564,187 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series A Preferred Stock | 7,127,019 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series B Preferred Stock | 1,333,975 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series B-1 Preferred Stock | 513,067 | $0.00 | - | |
| Carl L. Gordon - Director | Other | Series C Preferred Stock | 256,448 | $0.00 | - | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 10,690,530 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 2,000,962 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 769,601 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 564,187 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 300,249 footnote F2 | $17.00 | $5.10M | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 7,127,019 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 1,333,975 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 513,067 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 256,448 | - footnote F1 | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 61,516 footnote F2 | $17.00 | $1.05M | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 588,235 footnote F2 | $17.00 | $10.00M | |
| ORBIMED ADVISORS LLC - Director | Other | Series A Preferred Stock | 10,690,530 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series B Preferred Stock | 2,000,962 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series B-1 Preferred Stock | 769,601 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series C Preferred Stock | 564,187 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series A Preferred Stock | 7,127,019 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series B Preferred Stock | 1,333,975 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series B-1 Preferred Stock | 513,067 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series C Preferred Stock | 256,448 | $0.00 | - | |
| ||||||
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Common Stock | 3,334,938 | - footnote F1 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Common Stock | 1,113,666 | - footnote F1 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Common Stock | 512,897 | - footnote F1 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Open-market purchase | Common Stock | 592,593 | $17.00 | $10.07M | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Common Stock | 1,538,691 | - footnote F1 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Open-market purchase | Common Stock | 414,814 | $17.00 | $7.05M | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Common Stock | 1,667,468 | - footnote F1 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Common Stock | 169,001 | - footnote F1 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Open-market purchase | Common Stock | 592,593 | $17.00 | $10.07M | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Series B Preferred Stock | 3,907,547 | $0.00 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Series B-1 Preferred Stock | 1,304,883 | $0.00 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Series C Preferred Stock | 600,962 | $0.00 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Series C Preferred Stock | 1,802,885 | $0.00 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Series B Preferred Stock | 1,953,773 | $0.00 | - | |
| SR ONE CAPITAL MANAGEMENT, LLC - 10% Owner | Other | Series B-1 Preferred Stock | 198,019 | $0.00 | - | |
| ||||||
| Simeon George - Director | Other | Common Stock | 3,334,938 | - footnote F1 | - | |
| Simeon George - Director | Other | Common Stock | 1,113,666 | - footnote F1 | - | |
| Simeon George - Director | Other | Common Stock | 512,897 | - footnote F1 | - | |
| Simeon George - Director | Open-market purchase | Common Stock | 592,593 | $17.00 | $10.07M | |
| Simeon George - Director | Other | Common Stock | 1,538,691 | - footnote F1 | - | |
| Simeon George - Director | Open-market purchase | Common Stock | 414,814 | $17.00 | $7.05M | |
| Simeon George - Director | Other | Common Stock | 1,667,468 | - footnote F1 | - | |
| Simeon George - Director | Other | Common Stock | 169,001 | - footnote F1 | - | |
| Simeon George - Director | Open-market purchase | Common Stock | 592,593 | $17.00 | $10.07M | |
| Simeon George - Director | Other | Series B Preferred Stock | 3,907,547 | $0.00 | - | |
| Simeon George - Director | Other | Series B-1 Preferred Stock | 1,304,883 | $0.00 | - | |
| Simeon George - Director | Other | Series C Preferred Stock | 600,962 | $0.00 | - | |
| Simeon George - Director | Other | Series C Preferred Stock | 1,802,885 | $0.00 | - | |
| Simeon George - Director | Other | Series B Preferred Stock | 1,953,773 | $0.00 | - | |
| Simeon George - Director | Other | Series B-1 Preferred Stock | 198,019 | $0.00 | - | |
| ||||||
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Common Stock | 8,908,775 | - footnote F1 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Common Stock | 1,667,469 | - footnote F1 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Common Stock | 513,067 | - footnote F1 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Common Stock | 153,868 | - footnote F1 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Common Stock | 307,738 | - footnote F1 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Common Stock | 307,738 | - footnote F1 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Series A Preferred Stock | 10,438,412 | $0.00 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Series B Preferred Stock | 1,953,774 | $0.00 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Series B-1 Preferred Stock | 601,161 | $0.00 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Series C Preferred Stock | 180,288 | $0.00 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Series C Preferred Stock | 360,577 | $0.00 | - | |
| LAV Biosciences Fund V, L.P. - 10% Owner | Other | Series C Preferred Stock | 360,577 | $0.00 | - | |
| ||||||
| Rui (Nmn) Zhu - Officer | Grant or award | Employee Stock Option (right to buy) | 512,076 | $0.00 | - | |
| Alan Robert Macleod - Officer | Grant or award | Employee Stock Option (right to buy) | 170,692 | $0.00 | - | |
| Ryan Fisk - Officer | Grant or award | Employee Stock Option (right to buy) | 170,692 | $0.00 | - | |
| Zhen Li - Officer | Grant or award | Employee Stock Option (right to buy) | 1,024,152 | $0.00 | - | |
| Robert William Ackles - Officer | Grant or award | Employee Stock Option (right to buy) | 85,346 | $0.00 | - | |
Item 3.02, 5.03, 8.01, 9.01
ADRX insider trading FAQ
What is the latest insider trade for ADRX?
ADARx Pharmaceuticals, Inc. (ADRX) had 11 insider filings in the last 90 days, with the most recent on 2026-09-30. The full record for ADRX runs to 11 Form 4 filings, the earliest from 2026-09-28. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ADRX stock?
13 insider purchases of ADRX were filed in the last 90 days, totaling $87.75M.
How many insiders are selling ADRX stock?
No insider sales of ADRX were filed in the last 90 days.
Where can I see ADRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ADRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Erez Chimovits view on EDGAR
- - Carl L. Gordon view on EDGAR
- - ORBIMED ADVISORS LLC view on EDGAR
- - SR ONE CAPITAL MANAGEMENT, LLC view on EDGAR
- - Simeon George view on EDGAR
- - LAV Biosciences Fund V, L.P. view on EDGAR
- - Rui (Nmn) Zhu view on EDGAR
- - Alan Robert Macleod view on EDGAR
- - Ryan Fisk view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where ADRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ADRX with a 7-day demo
- ADRX on your watchlist
- Every ADRX Form 4 filing on record
- Up to 3 months of ADRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
